Clinical trial
REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (With Baricitinib) for Long COVID Related Cognitive Impairment and ADRD (Alzheimer's Disease and Related Dementias)
NCT05858515 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (With Baricitinib) for Long COVID Related Cognitive Impairment and ADRD (Alzheimer's Disease and Related Dementias)
- Lead sponsor
- Vanderbilt University Medical Center
- Phase
- Phase 3
- Overall status
- Withdrawn
- Start date
- October 21, 2024
- Completion date
- December 30, 2029
- Enrollment
- 0 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.